Product Code: RP-ID-10086089 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10086089
Market Overview:
Global Blood Plasma Market - Analysis By Type (Immunoglobulins - IV+SC, Albumin, Factor VIII - Plasma Derived), By Region, By Country (2018 Edition): Opportunities and Forecast 2030
" The global blood plasma market is estimated to be valued at more than ~USD 30 billion by end of 2021 expected to expand at a compound annual growth rate of 10% from 2022to 2030. Plasma is the liquid component of blood, composed of water and plasma components, such as immunoglobulin. , Electrolytes, glucose, clotting factors, electrolytes and hormones. It plays a vital role in maintaining electrolyte and osmotic balance, while preventing infections and blood diseases in the body. Plasma derivatives are specific protein concentrates that require pooling of plasma from a large number of donors. For example, they need more than one hundred plasma donations to produce enough immunoglobulin to treat patients with weakened immune function for one year. They are obtained through a fractional distillation process in which the protein concentrate is separated and then used in the clinic.
MARKET DYNAMICS:
The growth of the global plasma derivatives market is mainly driven by the increasing prevalence of life-threatening diseases, especially hemophilia. Other factors driving market growth include increased adoption of plasma-derived products, an increase in the global elderly population, and increased awareness of blood and plasma donations. However, factors such as the high cost of plasma derivative therapy and the postoperative risks associated with plasma replacement therapy hinder the growth of the market. On the contrary, the development of improved methods for the preservation of plasma derivatives and advanced fractionation procedures and the huge potential of untapped markets in emerging economies are expected to provide profitable growth opportunities for the market.
MARKET SEGMENTATION:
Based on type, application, end user and region. According to the type, the market is divided into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, etc. The immunoglobulin segment accounted for the largest market share in 2020, and this trend is expected to continue throughout the forecast period. On the other hand, the albumin market segment is expected to grow at a significant compound annual growth rate of 9% during the forecast period.
By application, the market is divided into hemophilia, hypogammaglobulinemia, immunodeficiency, von Willebrand disease (VWD) and other applications. The immunodeficiency disease segment accounted for the largest market share in 2020, while the hemophilia segment is expected to record the highest growth rate during the forecast period. According to different end users, the market is divided into hospitals, clinics and other end users. Hospitals had the largest market share in 2020, and the clinic sector is expected to record the highest growth rate during the forecast period. Divided by region, studied the markets of North America, Europe, Asia Pacific and LAMEA.
North America accounted for the largest market share in 2020, followed by Europe. On the other hand, due to the high population base, increased disposable income, and increased patient awareness of plasma derivatives, the Asia-Pacific region is expected to dominate the market during the review period. In addition, Asia is a continent that has become the center of life-threatening diseases. Other participants in the value chain (these participants are not described in the report and can be included on request) include China Biologic Products, Inc., Kedrion Biopharma, Inc., BDI Pharma, Inc., Bayer AG, and Hualan Biological Engineering , Inc..
MAIN ADVANTAGE:
The study conducted an in-depth analysis of the global plasma derivatives market, including current trends and future forecasts from 2022-2030, to clarify the upcoming investment pockets and comprehensive analysis of factors that promote and inhibit market growth. It provides the basic factors for changing market scenarios, increasing opportunities, and identifying key companies that can influence the market on a global and regional scale. Conducted a profile analysis of the main players and thoroughly analyzed their strategies to understand the competitive prospects of the market. .
THE KEY MARKET SEGMENTATION OF PLASMA DERIVATIVES :
by type Albumin Factor VII F Factor IX Immunoglobulin Hyperimmune globulin Other by application Hemophilia Hypogammaglobulinemia Willebrand disease (vWD) Immunodeficiency disease End user hospital Other applications End user clinic"
CSL Limited, Baxter International, Grifols S.A, Octa Pharma, Emergent Bio-solutions, Antaris Pharma, AMAG Pharma, Biota Pharma, Bio delivery Science International, Biotest A.G.
Related Reports
Proof of Quality & Reliability
